BLOG

The Xyzagen Blog

Stay ahead of emerging trends in drug development with Xyzagen’s expert insights, regulatory interpretations, and scientific thought leadership.

Apr 07

Model-Informed Drug Development and the Shift Toward Fewer Trials and Reduced Toxicology Testing

By e-web XYZ Blog

Model-Informed Drug Development (MIDD) is reshaping regulation. Learn how ICH M15 and FDA flexibility are reducing Phase 3 trial requirements:

READ FULL BLOG

Blog

Antibiotic Resistance: Why We Need New Antibiotics

Antibiotic resistance is accelerating worldwide, driven by multidrug-resistant gram-negative bacteria and a limited pipeline of new therapies. Learn more:

READ FULL BLOG

Choosing the Right ADA Assay for Ocular Biologics: Ligand Binding vs. Cell-Based Assays

For ophthalmic biologics and gene therapies administered by intravitreal injection, understanding immunogenicity is critical. These therapies can trigger an immune…

READ FULL BLOG

Understanding the Four Key Disciplines Behind Nonclinical PK Studies

When it comes to bringing new therapies from concept to initial clinical trials, understanding how a drug behaves in the…

READ FULL BLOG

2025 Drug Development Trends: The Evolution of Innovation – A Xyzagen Industry Forecast

The drug development landscape is currently undergoing a major transformation, driven by advanced modeling, real-time bioanalysis, and cutting-edge therapeutic strategies.…

READ FULL BLOG

Welcome to Xyzagen: Your Partner in Early Drug Development and Beyond

Xyzagen is a boutique, client-focused, consulting and contract research organization (CRO), providing integrated support across the full spectrum of drug…

READ FULL BLOG